Several beneficial effects of PPARγ agonists in reducing multiple asthma features, such as AHR, leukocyte infiltration, mucus overproduction, infiltration of lung DCs, proliferation of effector T cells, adhesion molecules and pro-inflammatory cytokines have been observed in various murine asthma models (137–144). This evidence concerns the gene PPARG and asthma.